Brief: Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical
02/12/2025 13:55
Dec 2 (Reuters) - Silexion Therapeutics Corp SLXN.O: SILEXION THERAPEUTICS RECEIVES POSITIVE FEEDBACK FROM GERMAN HEALTH AUTHORITY ON DESIGN OF PHASE 2/3 CLINICAL TRIAL IN PANCREATIC CANCER SILEXION THERAPEUTICS CORP - ON TRACK TO INITIATE PHASE 2/3 TRIAL IN H1 2026 SILEXION THERAPEUTICS CORP - REGULATORY SUBMISSIONS IN ISRAEL BY Q4 2025, GERMANY BY Q1 2026 Source text: ID:nGNX1n8HTR Further company coverage: SLXN.O ((Reuters.Briefs@thomsonreuters.com;))